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Intramolecular oxidative amination of readily accessible 
aminocyclooct-4-enes provides rapid and regioselective 
access to the 9-azabicyclo[4.2.1]nonane framework 
characteristic of the natural product anatoxin-a (1). This 
has enabled the synthesis of sp3-rich chemical scaffolds 
suitable for diversification. A library of 881 lead-like 
compounds is reported alongside a formal synthesis of 
anatoxin-a (1).  
 
The structure of anatoxin-a (1) was unambiguously determined in 1977 through the combination of X-ray crystallographic1 
and spectroscopic2 analysis. This potent neurotoxin is produced by certain strains of the freshwater blue-green algae 
Anabena flos-aquae and has been responsible for fatal poisoning of animal life.3 Also known as “Very Fast Death Factor”, 
anatoxin-a (1) causes death by respiratory paralysis with an LD50 (intraperitoneal, mouse) of 0.2 mg/kg, with a survival time 
of 4-7 minutes.4 The natural compound acts as a mimic for acetylcholine and is a potent and irreversible agonist for the 
nicotinic acetylcholine receptor (nAChR).5 As acetylcholine deficiency is implicated in diseases such as Alzheimer’s, analogues 
of anatoxin-a (1) possessing lower levels of toxicity may have potential in the treatment of neurological disorders.6 Paired 
with its significant biological properties, the compound’s unusual structure has prompted much synthetic interest; a number 
of distinct approaches to anatoxin-a (1) and its analogues have been devised.7 Since the topic was reviewed in 2006,8 there 
have been a considerable number of total/formal syntheses reported including our own two-directional approach9 and a 
contemporary example (2016) that utilises a novel formal amide insertion strategy.10 One commonly employed approach is 
to construct the 9-azabicyclo[4.2.1]nonane framework through the ring closure of an aminocyclooct-4-ene (Fig. 1), however 
there are drawbacks to each of the methods reported to date. 
 
 
 
 
 
 
Fig. 1 – Ring closure of aminocyclooct-4-enes for the synthesis of anatoxin-a (1) and chemical scaffolds for library 
generation.  
An aminocarbonylation strategy was reported by Ham in 1998,11 however this heterocyclisation was observed not 
to be regioselective. A series of reports by Parsons12 saw the development of a selenium-mediated ring closure, 
however this approach requires stoichiometric quantities of toxic phenylselenyl chloride. Ho13 reported a catalytic 
palladium mediated cyclisation of a corresponding trans-derivative, although yields were hampered by the 
formation of an undesired tricyclic side-product.  
 
As part of our studies into the synthesis of chemical scaffolds for drug discovery,14 we set out to develop a catalytic 
and selective protocol for the heterocyclisation of aminocyclooct-4-enes. It was envisaged that a regioselective and 
high-yielding protocol would expediate entry to series of 9-azabicyclo[4.2.1]nonane derived chemical scaffolds that 
could be further derivatised to generate a lead-like compound library. Small molecule libraries are highly desired in 
early-stage probe- and drug-discovery screening programmes15 and as part of our work under the European Lead 
Factory16 we have been engaged in the development of facile synthetic routes to chemical scaffolds that are suitable 
for diversification into high Fsp3 (fraction of sp3-hybridised carbon atoms)17 compound libraries. For these purposes 
we were drawn to the simplicity and concise nature of the heterocyclisation approach to the 9-
azabicyclo[4.2.1]nonane framework. We set out to investigate ring closure of the key precursor 2 under classical 
oxidative amination conditions with Pd(OAc)2, using Cu(OAc)2 as the terminal oxidant (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 – Catalyst/solvent optimisation. Reactions were performed on a 0.1 mmol scale. Yields were determined by 
quantitative 1H NMR spectroscopy with 1,3,5-trimethoxybenzene as an internal standard.  
Moderate yields of the desired product 3 were obtained using THF and PhMe as solvents (30% and 37% 
respectively). Changing to MeCN (Entry 3) gave an excellent conversion but DMF was found to be the superior 
solvent for this transformation, providing access to the 9-azabicyclo[4.2.1]nonane ring system with complete 
selectivity and quantitative conversion (Entry 4). Reducing the palladium loading to 2.5 mol% had a significantly 
detrimental effect on the yield (43%) and when the reaction was performed in the absence of palladium (Entry 6) 
or in the presence of Ru(II) and Rh(III) complexes (Entries 7-8), no cyclisation products could be detected. With the 
optimised conditions in hand, the substrate scope of the transformation was investigated (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry [M] (mol%) 
Cu(OAc)2 
(eq.) 
Solvent Yield 
1 Pd(OAc)2 (5) 2.1 THF 30% 
2 Pd(OAc)2 (5) 2.1 PhMe 37% 
3 Pd(OAc)2 (5) 2.1 MeCN 95% 
4 Pd(OAc)2 (5) 2.1 DMF 99% 
5 Pd(OAc)2 (2.5) 2.1 DMF 43% 
6 - 2.1 DMF - 
7 [RuCl2(p-cymene)]2 (2.5) 2.5 DMF - 
8 [RhCp*Cl2]2 (2.5) 2.5 DMF - 
Fig. 2 – Investigation into the substrate scope of the transformation. Yields are for isolated material obtained following 
column chromatography. 
Initially we attempted exchanging the N-tosyl functionality for the more readily de-protected carboxybenzyl (Cbz) 
group. In this case, the desired product 4 was obtained in a moderate yield of 39%. Benzoyl protection was 
considerably better tolerated, yielding the desired product 5 in a much improved 75%. The electron rich N-benzyl 
substrate was observed to react with poor selectivity and the targeted 9-azabicyclo[4.2.1]nonane 7 could not be 
isolated from the complicated mixture of products. We were however able to obtain the over-oxidised dienyl 
derivative 8 and the bicyclo[3.3.1]nonane derivative 9, albeit in modest yields in each case. Sulfonamides were 
found to be the highest yielding and most selective substrates, which is consistent with reports from the literature 
on many other palladium-mediated alkene aminations.18 The N-mesyl and -tosyl derivatives 6 and 3 were obtained 
in 79% and 93% respectively. In light of these results, N-tosylated precursors were selected to further investigate 
the substrate scope of the transformation with regard to the R2 substituent (Fig. 2). We were delighted to obtain a 
good yield of 84% for the Weinreb amide functionalised derivative 10, which could likely serve as a useful 
intermediate for the synthesis of side chain-modified anatoxin-a (1) derivatives. Performing alkylation prior to ring 
closing was also demonstrated to be a viable strategy, with the methyl and phenyl ketones 11 and 12 being isolated 
in 88% and 77% respectively.  
 
It was deemed prudent to focus the efforts of library synthesis on the high yielding and selective N-sulfonyl substrates. 
Furthermore, it was anticipated that the inherent stability of the sulfonamide functionality would help safeguard against the 
expected toxicity of the N-H derivatives. It was decided that the strategy for library synthesis would involve a series of 
sulfonylation reactions for decoration of the first point of diversity, with R2 becoming the main diversity generating vector 
to be explored. As such, the β-amino esters 13/14 were prepared according to a modified procedure of Choi19 and then 
treated with a range of sulfonyl chlorides. The selected examples represent alkyl, aryl (electron poor and rich) and hetro-aryl 
sulfonamide substitutions (Scheme 1, A-E). In each case sulfonylation proceeded smoothly and the products 2/15b-e were 
isolated in 76-99% yield. Under our optimised conditions, the oxidative amination of 2/15b-e gave excellent yields (79-93%) 
and regioselectivities (>20:1). 
 
Scheme 1 – The synthesis and derivatisation of chemical scaffolds for the generation of a 9-azabicyclo[4.2.1]nonane 
compound library. 
Next, to increase the “lead-likeness” of the final library the metabolically labile alkene functionality was removed via 
hydrogenation over palladium on carbon. In the penultimate step of library synthesis, base-mediated ester hydrolysis was 
employed to yield the carboxylic acid functionalised scaffolds 17a-e in good to excellent yields (72-95% over two steps). 
With the acids 17a-e in hand, the feasibility of a library synthesis via HATU-mediated amidation in plate-format was 
investigated. From the 5 scaffolds 17a-e, 15 test reactions were performed using a selection of cyclic, acyclic and 
aromatic amines  (See Supporting Information). The reaction mixtures were analysed by UPLC, filtered and purified 
by preparative HPLC, with purities of 85-100% as determined by LCMS. The stability of the amidation products was 
assessed by comparison of the 1H NMR spectra obtained before and after storage in DMSO-d6 at r.t. for 7 days. In 
each case no significant change could be observed. By utilising the general strategy for library synthesis described 
herein, a library of 881 9-azabicyclo[4.2.1]nonane derivatives were produced (ca. 0.1 mmol each) to be 
incorporated into the European Lead Factory’s screening programme. Computational assessment of the library 
indicates that it is largely Lipinski’s rule of five compliant, with an average molecular weight of 445.6 Da and cLogP 
of 2.48. The library also has a high degree of three-dimensionality and bond-saturation, with an average Fsp3 of 
0.56 (Fig. 3). In recent years there has been increased recognition of the importance of Fsp3 when designing 
compound libraries for lead identification. Increased bond saturation in general, as a measure of complexity, has 
been shown to correlate well with clinical success as compounds transition through the drug-discovery process.17 
With an average Fsp3 of 0.56, this library compares favourably to compounds in the discovery phase (average Fsp3 
= 0.36) and to marketed drugs (average Fsp3 = 0.47).17  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 – cLogP vs MW (left) and Fsp3 (right) plots of the produced 881 membered compound library. 
 
We were also compelled to apply the oxidative amination conditions to the synthesis of anatoxin-a (1). Parsons’ 
2000 synthesis12a utilised a selenium-mediated ring closure of the N-Boc methyl ketone 18 to construct the 
9-azabicyclo[4.2.1]nonane framework (Scheme 2). The intermediate selenide was not isolated but instead treated 
with H2O2, promoting oxidation and elimination to yield the key aza-bridged bicycle 19 in 55% over two steps. 
Interestingly, despite the report that PdCl2, Pd(OAc)2 and RhCl3 were unsuccessful at bringing about the 
heterocyclisation of 18, we were delighted to observe that utilisation of our optimised oxidative amination 
conditions allowed the isolation of 19 in a much improved 86% yield. This was achieved in a single synthetic 
operation and constitutes a useful refinement to the seminal work of Parsons12a and Rapoport.7b 
 
 
Scheme 2 – Application of the optimised oxidative amination conditions to the formal synthesis of anatoxin-a (1). 
In conclusion, an improved method for the intramolecular oxidative amination of aminocyclooct-4-enes is reported 
for formation of the biologically relevant 9-azabicyclo[4.2.1]nonane framework. The reaction is generally high 
yielding, has good substrate scope and proceeds under a cheap and “ligand-free” catalytic manifold. The protocol 
was applied to the synthesis of a series of chemical scaffolds, which were further derivatised to form a lead-like 881 
membered compound library. The oxidative amination methodology was then applied to a formal synthesis of 
anatoxin-a (1), facilitating an improved yield and increased operational simplicity.  
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